Phathom Pharmaceuticals, Inc. EPS Growth (diluted)

EPS Growth (diluted) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS Growth (diluted) growth rates and interactive chart. Year over year growth in diluted earnings per share.

Highlights and Quick Summary

  • EPS Growth (diluted) for the quarter ending June 29, 2021 was -56.25% (a 2.57% increase compared to previous quarter)
  • Year-over-year quarterly EPS Growth (diluted) decreased by -163.18%
  • Annual EPS Growth (diluted) for 2020 was 62.4% (a -100.3% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS Growth (diluted) of Phathom Pharmaceuticals, Inc.

Most recent EPS Growth (diluted)of PHAT including historical data for past 10 years.

Interactive Chart of EPS Growth (diluted) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EPS Growth (diluted) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -56.25% -54.84%
2020 60.1% 89.03% 62.4%
2019 -20540.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.